Related Experiment Video

Updated: Sep 25, 2025

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

8.1K

Characterization of anticancer drug resistance by reverse-phase protein array: new targets and strategies

Ann M Cathcart1,2, Hannah Smith1, Marilyne Labrie1,3

  • 1Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.

Expert Review of Proteomics
|April 25, 2022
PubMed
Abstract

Insights

Reverse-phase protein arrays (RPPA) help understand cancer drug resistance by analyzing proteomic changes. This proteomic approach is key to improving precision oncology and patient outcomes.

Area of Science:

  • Oncology
  • Proteomics
  • Cancer Biology

Background:

  • Drug resistance remains a significant obstacle in cancer therapy.
  • Tumor adaptation at the proteomic level contributes to therapeutic resistance.
  • Precision oncology requires more than genetic sequencing to overcome resistance.

Purpose of the Study:

  • To review the role of Reverse-Phase Protein Arrays (RPPA) in understanding and overcoming cancer drug resistance.
  • To highlight RPPA's contributions to studying resistance mechanisms against various targeted therapies.
  • To discuss the integration of proteomic data for advancing precision oncology.

Main Methods:

  • Literature review of studies utilizing RPPA for cancer drug resistance research.
  • Analysis of RPPA applications in resistance to PARP inhibitors, BRAF inhibitors, and immune checkpoint inhibitors.
  • Inclusion of data from breast cancer investigational therapies and I-SPY trials.

Main Results:

  • RPPA enables high-throughput proteomic analysis, crucial for understanding resistance.
  • RPPA effectively detects phosphoproteins and validates key cellular pathways involved in drug resistance.
  • The review details RPPA's specific contributions to understanding resistance to several targeted therapies.

Conclusions:

  • RPPA is a powerful tool for proteomic analysis in cancer drug resistance research.
  • Combined genomic and proteomic analyses are essential for advancing precision oncology.
  • Integrating RPPA data can lead to improved therapeutic strategies and patient outcomes.
Keywords:
BRAF inhibitorPARP inhibitorProteomicsRPPAadaptive resistancedrug resistanceimmune checkpoint inhibitorprecision oncologyreverse-phase protein array

More Related Videos

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

10.7K
The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers12:22

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

33.7K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K